Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217.

ABSTRACT: Nowadays, there is an unmet need for reliable and minimally-invasive diagnosis tools capable of detecting Alzheimer's disease at early stages. Such tools could significantly reduce the reliance on confirmatory tests that are invasive and costly, such as cerebrospinal fluid (CSF) biomarkers and neuroimaging. The aim of this study is to validate previously developed diagnosis tools (multivariate models and plasma p-Tau217 levels) in three independents cohorts. For this, a cohort was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) including some variables (age, Apolipoprotein E (ApoE) genotype, plasma p-Tau217, CSF biomarkers) (n = 113); and two cohorts from cognitive disorders units (Hospital Universitari i Politècnic La Fe (HUiPLaFe, n = 163), Hospital Doctor Peset (n =

SUBMITTER: Marti-Navia A 

PROVIDER: S-EPMC12796396 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature